Home
Invicro

Invicro Market Share Analysis for January 2026

Perceptive, the industry’s most trusted provider of preclinical to late-phase imaging solutions, Randomization & Trial Supply Management(RTSM)

Health > Biotechnology and Pharmaceuticals

Domaininvicro.com

Year Founded2008

Employees201 - 500

Annual Revenue$100M - $200M

Invicro

Invicro (including company regionals)

invicro.com

See more website traffic and engagement information

Invicro Revenue up to January 2026 is 100M - 200M

revenue generated by Invicro top domains

Invicro top domains revenue over 3 years

Revenue for Invicro top domains

invicro.com100M - 200M

See more with Sales Intelligence

Total visits to Invicro's top domains

Understand Invicro market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

invicro.com--

See more with Sales Intelligence

Avg. visit duration in Invicro's top domains

Analyze Invicro engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Invicro's top domains

See how Invicro keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

invicro.com--

See more with Sales Intelligence

Invicro top competitors by domain

Top similar sites in January 2026, ranked by their affinity

perceptive.comCompany NamePerceptiveEmployees1001 - 5000HQUnited Kingdom, LondonAnnual revenue$15M - $25MTotal visits23.9KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Invicro

These are the website technologies, by industry, used by Invicro top domains

Advertising (7)

DoubleClick

Widget (4)

Twemoji

Content Management System (3)

WordPress

Marketing (3)

Google Marketing Platform

More Technologies

11

See all

News & Signals from Invicro

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCalyx acquires Invicro.Nottingham-based Calyx, a provider of medical imaging services and IRT/RTSM (Interactive Response Technology/Randomised Trial Supply Management) to drug developers, is acquiring 100% of Invicro, a next-generation quantitative imaging biomarker company and development partner to pharma sponsors, from its current owner, REALM IDx, a US-based healthcare company pioneering the field of integrated diagnostics,

NewsInvicro partners with Akoya Biosciences, Inc..“Invicro is excited to partner with Akoya for early access to the new PhenoCode Signature Panels, which will simplify approaches to create rich, contextual biomarker data and help us accelerate the discovery and validation of immunotherapy biomarkers,” said Joseph Krueger, PhD, Vice President of Invicro’s Advanced Pathology Services.

NewsImaginAb, Inc. partnered with Invicro on May 12th '22.ImaginAb Inc., a market-leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), today announced a new agreement with Invicro LLC, a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to supply clinical doses of ImaginAb's investigational CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab berdoxam) for use in clinical trials as part of Invicro's global core lab imaging service.